Drugs / NP-011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05387499 | Jun 2022 → Mar 2023 | myocardial infarction | Nexel Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NP-011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05387499 ↗ |
| Modality | Protein / enzyme biologic | “NP-011 is a truncated form of human MFG-E8 recombinant protein.” NCT05387499 ↗ |
| Route | Intravenous | “Route of Administration: Intravenous” NCT05387499 ↗ |